TecTraum Inc., dedicated to providing the world’s first point-of-care treatment for concussions, announced the completion of the pro2cool®clinical trial.

The FDA has designated TecTraum's pro2cool® - dedicated to providing the world’s first point-of-care treatment for concussions - as a Breakthrough Device.

Nottingham Spirk exhibited at CES for the first time in 2019, and we invited a few of our client-partners to show the world what we achieved together.

This month we are featuring our Biomedical Engineering Team and their thoughts about Nottingham Spirk's approach to medical device design.